Halozyme Therapeutics (HALO) Stock: Buy, Sell, or Hold?
HALO - Halozyme Therapeutics, Inc.
$106.94
-3.46 (-3.13%)
âŧ
5d:
-7.19%
30d:
-0.72%
90d:
+34.6%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 02, 2026
30d
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HALO is fairly priced but lacks strong directional signals. At 8.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HALO is fairly priced but lacks strong directional signals. At 8.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$151.27
Based on 12.6% avg growth
INTRINSIC VALUE TODAY
$93.93
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $106.94, which is considered slightly low relative to its 30-day fair value range of $106.82 to $112.23. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.3) compared to its historical average (8.1). At these levels, the market is pricing in 8.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is currently testing key support at $106.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: HALO scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is currently testing key support at $106.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: HALO scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$106.82 -
$112.23
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
44.3%
Protect Your Profits
Holding HALO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BEARISH: Trading above Wall St target ($99.56)
- NEUTRAL: Trading at premium valuation - market expects 8.1% growth which is achievable
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$106.82 -
$112.23
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$106.84
Resistance Level
$116.85
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.29
Wall Street Target
$99.56
(-6.9%)
Revenue Growth (YoY)
47.7%
Earnings Growth (YoY)
42.9%
Profit Margin
24.9%
Valuation Premium vs History
+8.1% premium
PE vs Historical
10.3 vs 8.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.1%
(market-implied from PE analysis)
1-Year Target
$115.60
(+8%)
2-Year Target
$124.97
(+17%)
3-Year Target
$135.09
(+26%)
3-Yr Target (if PE normalizes)
(PE: 10â8)
PE COMPRESSION
$106.34
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 21.2%)
$377.24
(+253%)
Base:
(SPY PE: 10.3, Growth: 21.2%)
$190.28
(+78%)
Bear:
(PE: 8.1, Growth: 21.2%)
$149.79
(+40%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 32.38 | Current EPS (TTM): $3.41
Bull Case
$242.88
(+127%)
Analyst growth 100.0%, PE expands to 35.6
Base Case
$220.80
(+107%)
Market implied 100.0%, PE stable at 32.4
Bear Case
$75.07
(-30%)
Severe decline -20.0%, PE contracts to 27.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 12:48 AM ET
Data refreshes hourly during market hours. Next update: 1:48 AM
Data refreshes hourly during market hours. Next update: 1:48 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Helen Torley
SELL
10000 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 47 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 69 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 58 HOLD |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
